Back to results
US 6,183,949 B2Granted
HCV peptide antigens and methods for the determination of HCV
AssigneeRoche Diagnostics GmbH
InventorsChristoph Seidel, Gertraud Ehrlich-Weinreich, Hubert Bayer, Ursula H Wienhues, Günther Gerhard Jung, Hans Georg Ihlenfeldt
Life of this patent
Estimating the term…
Abstract
Novel HCV peptide antigens are described representing partial sequences of the C-100-3 and env/core with C-regions. These peptide antigens are suitable for the determination of HCV antibodies as immunogens for the production of antibodies against HCV and as vaccines for the production of vaccines against HCV.
Claims2
A method for determining the presence of an HCV specific antibody in a sample, comprising the steps of
- incubating said sample with at least one HCV peptide antigen under conditions favoring binding of any HCV antibody in said sample to said at least one HCV peptide antigen and determining such binding in the incubated sample as a measure of the presence of said HCV specific antibody, wherein said at least one HCV specific peptide antigen is selected from the group consisting of the amino acid sequences shown in SEQ ID NOS. 13, 14, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28 and 32.
A composition comprising a combination of at least two HCV peptide antigens selected from the group consisting of SEQ ID NOS:
- 13, 14, 24, 25, 26, 27 and 28.
- TABLE II Peptide C100-3 Region Core env. Region SEQ ID SEQ ID SEQ ID SEQ ID SEQ ID SEQ ID SEQ ID SEQ ID SEQ ID SEQ ID SEQ ID Serum Ortho NO:
- 1 NO:
- 3 NO:
- 5 NO:
- 4 NO:
- 11 NO:
- 13 NO:
- 16 NO:
- 26 NO:
- 27 NO:
- 22 NO:
- 23 Ortho S1 • ◯ [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] 4 S2 2 ◯ ◯ [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] ◯ 4 S3 1 ◯ [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] 4 S4 (*) • — S5 +/− [Circlesolid] ◯ [Circlesolid] 4 S6 1 [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] ◯ 4 S7 (*) • □ — S8 +/− ▪ □ — S9 • [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] 4 S10 +/− □ — S11 +/− ◯ [Circlesolid] [Circlesolid] [Circlesolid] ◯ 3 S12 2 ◯ [Circlesolid] ◯ 3 S13 4 [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] ◯ [Circlesolid] [Circlesolid] [Circlesolid] 4 S14 +/− [Circlesolid] [Circlesolid] ◯ 4 S15 +/− [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] 4 S16 4 [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] ◯ [Circlesolid] [Circlesolid] [Circlesolid] 4 S17 4 [Circlesolid] ◯ [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] 4 S18 2 [Circlesolid] 3 S19 (*) +/− — S20 1 □ □ ▪ □ +/− S21 +/− [Circlesolid] [Circlesolid] ◯ [Circlesolid] 4 S22 • ◯ [Circlesolid] 4 S23 3 [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] 4 S24 4 [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] 4 S25 1 [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] 4 D01 ◯ [Circlesolid] [Circlesolid] [Circlesolid] ◯ [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] ◯ 01-4215333 [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] 56-138481 [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] ▪ □ 19971 [Circlesolid] ◯ [Circlesolid] [Circlesolid] 19975 [Circlesolid] ◯ [Circlesolid] [Circlesolid] ◯ ◯ ▪ □ ▪ 19975 [Circlesolid] [Circlesolid] [Circlesolid] ▪ 20004 [Circlesolid] 20009 [Circlesolid] [Circlesolid] [Circlesolid] ◯ [Circlesolid] [Circlesolid] ▪ □ RS (*) HO (*) AB (*) TABLE III Peptide antegens SEQ ID SEQ ID SEQ ID SEQ ID SEQ ID SEQ ID SEQ ID NO:
- 3, Serum NO:
- 3 NO:
- 4 NO:
- 11 NO:
- 12 NO:
- 16 26 4, 11, 12, 16 LL485561 LL488301 [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] LL491001* LL493411* LL496131* LL504111* FF194591* FF206011* FF200311 [Circlesolid] ◯ ◯ [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] FF211511* FF210051 [Circlesolid] [Circlesolid] [Circlesolid] FF804511* B1 nt [Circlesolid] [Circlesolid] ◯ [Circlesolid] B2 nt ◯ [Circlesolid] [Circlesolid] ◯ [Circlesolid] B3 nt [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] B4 nt ◯ [Circlesolid] [Circlesolid] ◯ [Circlesolid] B5 nt [Circlesolid] ◯ [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] B6 nt [Circlesolid] [Circlesolid] B7 nt [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] B8 nt [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] B9 nt [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] B10 nt [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] B11 B12 [Circlesolid] [Circlesolid] [Circlesolid] B13 [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] B14 nt [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] B15 [Circlesolid] [Circlesolid] ◯ ◯ [Circlesolid] [Circlesolid] B16 [Circlesolid] [Circlesolid] ◯ [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] B17 [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] B18 nt [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] B19 nt [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] B20 ◯ ◯ [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] 01-421533 [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] S23 [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] * TABLE IV Peptide antigens SEQ ID SEQ ID SEQ ID SEQ ID NOS:
- 4, NOS:
- 4, NOS:
- 3, 4 NOS:
- 3, 4, Serum 12, 16 5, 11, 16 5, 11, 16 5, 11, 16, 26, 27 S1 [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] S2 [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] S3 [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] S4 (*) S5 [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] S6 [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] S7 (*) S8 ◯ S9 [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] S10 ◯ ◯ S11 [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] S12 [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] S13 [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] S14 [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] S15 [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] S16 [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] S17 [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] S18 [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] S19(*) S20 ◯ [Circlesolid] S21 [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] S22 [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] S23 [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] S24 [Circlesolid] [Circlesolid] [Circlesolid] [Circlesolid] (*) negative sera TABLE V Peptide SEQ ID NOS:
- 3, SEQ ID NOS:
- 6, SEQ ID NOS:
- Serum 4, 11, 16, 26 8, 13, 19, 28 24, 30, 31 1 + + − 2 − − − 3 + + + 4 + + + 5 − − + 6 − − − 7 + + + 8 − − − 9 + + − 10 + + − 11 + + − 12 + + + 13 + + − 14 + + − 15 + + − 16 + + − 17 − − − 18 − − + 19 + + + 20 + + − 21 + + − 22 + + + 23 + + + 24 + + − 25 + + − 26 + + + 27 + + − 28 + + − 29 − − − 30 − − − 31 − − − 32 + + − 33 − − − 34 + + + 35 + + + TABLE VI Peptide SEQ ID SEQ ID SEQ ID SEQ ID SEQ ID SEQ ID SEQ ID Serum NO:
- 6 NO:
- 8 NO:
- 13 NO:
- 18 NOS:
- 19, 20 NO:
- 28 NO:
- 30 1 + − + + + − − 2 + − + − − − − 3 − − − + + + − 4 + − + + + − − 5 − + + + + − − 6 − − − − − − − 7 − − − − − − − 8 − − − − − − − 9 + + + + + + + 10 − − − − − − − 11 + + + + + − − 12 − − − + + + + TABLE VII Peptide SEQ ID SEQ ID SEQ ID SEQ ID Serum NO:
- 10 NO:
- 14 NO:
- 15 NO:
- 18 1 + − − + 2 − − − + 3 − + + −
34 more elements
Dependencies are inferred from the claim text.